Zymeworks Receives Second Orphan Drug Designation for ZW25 in Gastric Cancer
Zymeworks announced that its lead product candidate, ZW25, has been granted orphan drug designation from the U.S. Food and Drug Administration (the “FDA”) in the treatment of gastric…
Read More...
Read More...